{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:22:54Z","timestamp":1792732974124,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,5,10]],"date-time":"2008-05-10T00:00:00Z","timestamp":1210377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1245\/s10434-008-9881-6","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T14:31:23Z","timestamp":1210343483000},"source":"Crossref","is-referenced-by-count":40,"title":["Isolated Hepatic Perfusion with 200\u00a0mg Melphalan for Advanced Noncolorectal Liver Metastases"],"prefix":"10.1245","volume":"15","author":[{"given":"Liselot B. J.","family":"van Iersel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els L.","family":"van Persijn van Meerten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G. J.","family":"Tijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk H.","family":"Hartgrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. K.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W. R.","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A. E. M.","family":"Tollenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. H.","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,10]]},"reference":[{"key":"9881_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.amjsurg.2003.04.007","volume":"187","author":"R Sutcliffe","year":"2004","unstructured":"Sutcliffe R, Maguire D, Ramage J, et\u00a0al. Management of neuroendocrine liver metastases. Am J Surg 2004; 187:39\u201346","journal-title":"Am J Surg"},{"key":"9881_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00000658-199906000-00008","volume":"229","author":"KO Shebani","year":"1999","unstructured":"Shebani KO, Souba WW, Finkelstein DM, et\u00a0al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999; 229:815\u201321","journal-title":"Ann Surg"},{"key":"9881_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/1097-0142(196109\/10)14:5<901::AID-CNCR2820140502>3.0.CO;2-Q","volume":"14","author":"CG Moertel","year":"1961","unstructured":"Moertel CG, Sauer WG, Dockerty MB, et\u00a0al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14:901\u201312","journal-title":"Cancer"},{"key":"9881_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0039-6257(88)90173-7","volume":"32","author":"KM Egan","year":"1988","unstructured":"Egan KM, Seddon JM, Glynn RJ, et\u00a0al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32:239\u201351","journal-title":"Surv Ophthalmol"},{"key":"9881_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/1097-0142(19830715)52:2<334::AID-CNCR2820520225>3.0.CO;2-E","volume":"52","author":"S Rajpal","year":"1983","unstructured":"Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983; 52:334\u20136","journal-title":"Cancer"},{"key":"9881_CR6","doi-asserted-by":"crossref","unstructured":"Assessment of metastatic disease status at death in 435\u00a0patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670\u20136","DOI":"10.1001\/archopht.119.5.670"},{"key":"9881_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/BF00316983","volume":"19","author":"I Ihse","year":"1995","unstructured":"Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995; 19:76\u201382","journal-title":"World J Surg"},{"key":"9881_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/BF00316981","volume":"19","author":"J Scheele","year":"1995","unstructured":"Scheele J, Stang R, Altendorf-Hofmann A, et\u00a0al. Resection of colorectal liver metastases. World J Surg 1995; 19:59\u201371","journal-title":"World J Surg"},{"key":"9881_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1148\/radiol.2211001624","volume":"221","author":"L Solbiati","year":"2001","unstructured":"Solbiati L, Livraghi T, Goldberg SN, et\u00a0al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221:159\u201366","journal-title":"Radiology"},{"key":"9881_CR10","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.2005.12.039","volume":"23","author":"E Berber","year":"2005","unstructured":"Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23:1358\u201364","journal-title":"J Clin Oncol"},{"key":"9881_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1001\/archsurg.141.2.181","volume":"141","author":"LM Sutherland","year":"2006","unstructured":"Sutherland LM, Williams JA, Padbury RT, et\u00a0al. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006; 141:181\u201390","journal-title":"Arch Surg"},{"key":"9881_CR12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/bjc.1990.404","volume":"62","author":"A Marinelli","year":"1990","unstructured":"Marinelli A, van de Velde CJ, Kuppen PJ, et\u00a0al. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 1990; 62:891\u20136","journal-title":"Br J Cancer"},{"key":"9881_CR13","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/bjs.4308","volume":"90","author":"J Rothbarth","year":"2003","unstructured":"Rothbarth J, Pijl ME, Vahrmeijer AL, et\u00a0al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003; 90:1391\u20137","journal-title":"Br J Surg"},{"key":"9881_CR14","first-page":"3062","volume":"6","author":"HR Alexander","year":"2000","unstructured":"Alexander HR, Libutti SK, Bartlett DL, et\u00a0al. A phase I\u2013II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6:3062\u201370","journal-title":"Clin Cancer Res"},{"key":"9881_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1054\/bjoc.2000.1175","volume":"82","author":"AL Vahrmeijer","year":"2000","unstructured":"Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et\u00a0al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 2000; 82:1539\u201346","journal-title":"Br J Cancer"},{"key":"9881_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00008390-200402000-00011","volume":"14","author":"SL Noter","year":"2004","unstructured":"Noter SL, Rothbarth J, Pijl ME, et\u00a0al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004; 14:67\u201372","journal-title":"Melanoma Res"},{"key":"9881_CR17","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.surg.2004.06.044","volume":"136","author":"AC Grover","year":"2004","unstructured":"Grover AC, Libutti SK, Pingpank JF, et\u00a0al. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 2004; 136:1176\u201382","journal-title":"Surgery"},{"key":"9881_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.gassur.2003.11.005","volume":"8","author":"ED Feldman","year":"2004","unstructured":"Feldman ED, Wu PC, Beresneva T, et\u00a0al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 2004; 8:200\u20137","journal-title":"J Gastrointest Surg"},{"key":"9881_CR19","first-page":"6343","volume":"9","author":"HR Alexander Jr","year":"2003","unstructured":"Alexander HR Jr, Libutti SK, Pingpank JF, et\u00a0al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343\u20139","journal-title":"Clin Cancer Res"},{"key":"9881_CR20","first-page":"3062","volume":"6","author":"HR Alexander","year":"2000","unstructured":"Alexander HR, Libutti SK, Bartlett DL, et\u00a0al. A phase I\u2013II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6:3062\u201370","journal-title":"Clin Cancer Res"},{"key":"9881_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00008390-200402000-00011","volume":"14","author":"SL Noter","year":"2004","unstructured":"Noter SL, Rothbarth J, Pijl ME, et\u00a0al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004; 14:67\u201372","journal-title":"Melanoma Res"},{"key":"9881_CR22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ejso.2007.02.022","volume":"33","author":"LB Iersel van","year":"2007","unstructured":"van Iersel LB, Verlaan MR, Vahrmeijer AL, et\u00a0al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. Eur J Surg Oncol 2007; 33:874\u201381","journal-title":"Eur J Surg Oncol"},{"key":"9881_CR23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.jjco.a023243","volume":"26","author":"A Marinelli","year":"1996","unstructured":"Marinelli A, de Brauw LM, Beerman H, et\u00a0al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996; 26:341\u201350","journal-title":"Jpn J Clin Oncol"},{"key":"9881_CR24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0883-2897(87)90140-1","volume":"14","author":"RD Runia","year":"1987","unstructured":"Runia RD, de Brauw LM, Kothuis BJ, et\u00a0al. Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Int J Rad Appl Instrum B 1987; 14:113\u20138","journal-title":"Int J Rad Appl Instrum B"},{"key":"9881_CR25","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.1998.16.4.1479","volume":"16","author":"HR Alexander Jr","year":"1998","unstructured":"Alexander HR Jr, Bartlett DL, Libutti SK, et\u00a0al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16:1479\u201389","journal-title":"J Clin Oncol"},{"key":"9881_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et\u00a0al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205\u201316","journal-title":"J Natl Cancer Inst"},{"key":"9881_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.surg.2004.06.044","volume":"136","author":"AC Grover","year":"2004","unstructured":"Grover AC, Libutti SK, Pingpank JF, et\u00a0al. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 2004; 136:1176\u201382","journal-title":"Surgery"},{"key":"9881_CR28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0889-8553(21)00236-3","volume":"24","author":"PD King","year":"1995","unstructured":"King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am 1995; 24:969\u201390","journal-title":"Gastroenterol Clin North Am"},{"key":"9881_CR29","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO;2-J","volume":"76","author":"AY Bedikian","year":"1995","unstructured":"Bedikian AY, Legha SS, Mavligit G, et\u00a0al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665\u201370","journal-title":"Cancer"},{"key":"9881_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/00000421-199812000-00008","volume":"21","author":"LE Flaherty","year":"1998","unstructured":"Flaherty LE, Unger JM, Liu PY, et\u00a0al. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568\u201372","journal-title":"Am J Clin Oncol"},{"key":"9881_CR31","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s00262-004-0537-5","volume":"53","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Hellstrand K, Gehlsen K, et al. Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol Immunother 2004; 53:840\u20131","journal-title":"Cancer Immunol Immunother"},{"key":"9881_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.iio.0000195852.08453.de","volume":"46","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006; 46:151\u201366","journal-title":"Int Ophthalmol Clin"},{"key":"9881_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/annonc\/mdl009","volume":"17","author":"S Peters","year":"2006","unstructured":"Peters S, Voelter V, Zografos L, et\u00a0al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:578\u201383","journal-title":"Ann Oncol"},{"key":"9881_CR34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","volume":"98","author":"ES Gragoudas","year":"1991","unstructured":"Gragoudas ES, Egan KM, Seddon JM, et\u00a0al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383\u20139","journal-title":"Ophthalmology"},{"key":"9881_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s10620-006-8001-3","volume":"51","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Wu B, Ryan DP, et\u00a0al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006; 51:1033\u20138","journal-title":"Dig Dis Sci"},{"key":"9881_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","volume":"68","author":"CG Moertel","year":"1991","unstructured":"Moertel CG, Kvols LK, O\u2019Connell MJ, et\u00a0al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227\u201332","journal-title":"Cancer"},{"key":"9881_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","volume":"21","author":"E Rivera","year":"1998","unstructured":"Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998; 21:36\u20138","journal-title":"Am J Clin Oncol"},{"issue":"Suppl 1","key":"9881_CR38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","volume":"62","author":"K Oberg","year":"2000","unstructured":"Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000; 62(Suppl 1):92\u20137","journal-title":"Digestion"},{"key":"9881_CR39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"LK Kvols","year":"1986","unstructured":"Kvols LK, Moertel CG, O\u2019Connell MJ, et\u00a0al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663\u20136","journal-title":"N Engl J Med"},{"key":"9881_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/00001813-199410000-00001","volume":"5","author":"K Oberg","year":"1994","unstructured":"Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs 1994; 5:503\u201319","journal-title":"Anticancer Drugs"},{"key":"9881_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/02841869109092409","volume":"30","author":"K Oberg","year":"1991","unstructured":"Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30:503\u20137","journal-title":"Acta Oncol"},{"issue":"3 Suppl","key":"9881_CR42","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1007\/BF01536042","volume":"34","author":"A Vinik","year":"1989","unstructured":"Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34(3 Suppl):14S\u201327S","journal-title":"Dig Dis Sci"},{"key":"9881_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","volume":"36","author":"R Valkema","year":"2006","unstructured":"Valkema R, Pauwels S, Kvols LK, et\u00a0al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36:147\u201356","journal-title":"Semin Nucl Med"},{"key":"9881_CR44","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","volume":"26","author":"P Hellman","year":"2002","unstructured":"Hellman P, Ladjevardi S, Skogseid B, et\u00a0al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002; 26:1052\u20136","journal-title":"World J Surg"},{"key":"9881_CR45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2214\/ajr.181.4.1811005","volume":"181","author":"AR Henn","year":"2003","unstructured":"Henn AR, Levine EA, McNulty W, et\u00a0al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol 2003; 181:1005\u201310","journal-title":"AJR Am J Roentgenol"},{"key":"9881_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/jsre.2000.5988","volume":"95","author":"FJ Wessels","year":"2001","unstructured":"Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001; 95:8\u201312","journal-title":"J Surg Res"},{"key":"9881_CR47","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00268-002-6629-5","volume":"26","author":"E Berber","year":"2002","unstructured":"Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26:985\u201390","journal-title":"World J Surg"},{"key":"9881_CR48","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.surg.2004.06.044","volume":"136","author":"AC Grover","year":"2004","unstructured":"Grover AC, Libutti SK, Pingpank JF, et\u00a0al. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 2004; 136:1176\u201382","journal-title":"Surgery"},{"key":"9881_CR49","first-page":"830","volume":"51","author":"M Wettstein","year":"2004","unstructured":"Wettstein M, Vogt C, Cohnen M, et\u00a0al. Serotonin release during percutaneous radiofrequency ablation in a patient with symptomatic liver metastases of a neuroendocrine tumor. Hepatogastroenterology 2004; 51:830\u20132","journal-title":"Hepatogastroenterology"},{"key":"9881_CR50","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, et\u00a0al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577\u201380","journal-title":"Science"},{"key":"9881_CR51","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et\u00a0al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472\u201380","journal-title":"N Engl J Med"},{"key":"9881_CR52","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","volume":"358","author":"AT Oosterom van","year":"2001","unstructured":"van Oosterom AT, Judson I, Verweij J, et\u00a0al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421\u20133","journal-title":"Lancet"},{"key":"9881_CR53","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, et\u00a0al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329\u201338","journal-title":"Lancet"},{"key":"9881_CR54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0960-7404(00)00027-X","volume":"9","author":"SR Patel","year":"2000","unstructured":"Patel SR, Benjamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000; 9:67\u201370","journal-title":"Surg Oncol"},{"key":"9881_CR55","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s005350070004","volume":"35","author":"PG Tarazov","year":"2000","unstructured":"Tarazov PG. Transcatheter therapy of gastric cancer metastatic to the liver: preliminary results. J Gastroenterol 2000; 35:907\u201311","journal-title":"J Gastroenterol"},{"key":"9881_CR56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/000313480206800920","volume":"68","author":"M Bloomston","year":"2002","unstructured":"Bloomston M, Binitie O, Fraiji E, et\u00a0al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002; 68:827\u201331","journal-title":"Am Surg"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-008-9881-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-008-9881-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-008-9881-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-008-9881-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T06:51:47Z","timestamp":1684392707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-008-9881-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,10]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["9881"],"URL":"https:\/\/doi.org\/10.1245\/s10434-008-9881-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,10]]},"article-number":"1891"}}